Phage Therapy for Respiratory Infections: Opportunities and Challenges.
Antimicrobial resistance
Bacteriophage
Chronic infections
Phage therapy
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
21 May 2024
21 May 2024
Historique:
received:
29
01
2024
accepted:
13
04
2024
medline:
22
5
2024
pubmed:
22
5
2024
entrez:
21
5
2024
Statut:
aheadofprint
Résumé
We are entering the post-antibiotic era. Antimicrobial resistance (AMR) is a critical problem in chronic lung infections resulting in progressive respiratory failure and increased mortality. In the absence of emerging novel antibiotics to counter AMR infections, bacteriophages (phages), viruses that infect bacteria, have become a promising option for chronic respiratory infections. However, while personalized phage therapy is associated with improved outcomes in individual cases, clinical trials demonstrating treatment efficacy are lacking, limiting the therapeutic potential of this approach for respiratory infections. In this review, we address the current state of phage therapy for managing chronic respiratory diseases. We then discuss how phage therapy may address major microbiologic obstacles which hinder disease resolution of chronic lung infections with current antibiotic-based treatment practices. Finally, we highlight the challenges that must be addressed for successful phage therapy clinical trials. Through this discussion, we hope to expand on the potential of phages as an adjuvant therapy in chronic lung infections, as well as the microbiologic challenges that need to be addressed for phage therapy to expand beyond personalized salvage therapy.
Identifiants
pubmed: 38772946
doi: 10.1007/s00408-024-00700-7
pii: 10.1007/s00408-024-00700-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cystic Fibrosis Foundation
ID : 003397D122
Organisme : Cystic Fibrosis Foundation
ID : CHEN21F0
Organisme : Doris Duke Charitable Foundation
ID : 2023-0217
Pays : United States
Organisme : NIH HHS
ID : R01AI12492093
Pays : United States
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Murray CJL, Ikuta KS, Sharara F et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399:629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
doi: 10.1016/S0140-6736(21)02724-0
The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death . Accessed 17 Nov 2023
Drevinek P, Canton R, Johansen HK et al (2022) New concepts in antimicrobial resistance in cystic fibrosis respiratory infections. J Cyst Fibros 21:937–945. https://doi.org/10.1016/j.jcf.2022.10.005
doi: 10.1016/j.jcf.2022.10.005
pubmed: 36270946
Smith D, Gill A, Hall L (2021) Prevalence, pattern, risks factors and consequences of antibiotic resistance in COPD: a systematic review. J Chronic Obstr Pulm Dis. https://doi.org/10.1080/15412555.2021.2000957
doi: 10.1080/15412555.2021.2000957
Nosotti M, Tarsia P, Morlacchi LC (2018) Infections after lung transplantation. J Thorac Dis 10:3849–3868. https://doi.org/10.21037/jtd.2018.05.204
doi: 10.21037/jtd.2018.05.204
pubmed: 30069386
pmcid: 6051843
Inchingolo R, Pierandrei C, Montemurro G et al (2021) Antimicrobial resistance in common respiratory pathogens of chronic bronchiectasis patients: a literature review. Antibiot (Basel) 10:326. https://doi.org/10.3390/antibiotics10030326
doi: 10.3390/antibiotics10030326
Goss CH (2019) Acute pulmonary exacerbation in cystic fibrosis. Semin Respir Crit Care Med 40:792–803. https://doi.org/10.1055/s-0039-1697975
doi: 10.1055/s-0039-1697975
pubmed: 31659730
pmcid: 7528649
Flume PA, Mogayzel PJ, Robinson KA et al (2009) Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180:802–808. https://doi.org/10.1164/rccm.200812-1845PP
doi: 10.1164/rccm.200812-1845PP
pubmed: 19729669
Sanders DB, Bittner RCL, Rosenfeld M et al (2010) Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 182:627–632. https://doi.org/10.1164/rccm.200909-1421OC
doi: 10.1164/rccm.200909-1421OC
pubmed: 20463179
pmcid: 5450763
Ramsey BW, Pepe MS, Quan JM et al (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340:23–30. https://doi.org/10.1056/NEJM199901073400104
doi: 10.1056/NEJM199901073400104
pubmed: 9878641
Taccetti G, Francalanci M, Pizzamiglio G et al (2021) Cystic fibrosis: recent insights INTO inhaled antibiotic treatment and future perspectives. Antibiot (Basel) 10:338. https://doi.org/10.3390/antibiotics10030338
doi: 10.3390/antibiotics10030338
Langton Hewer SC, Smyth AR (2017) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004197.pub5
doi: 10.1002/14651858.CD004197.pub5
pubmed: 28440853
pmcid: 6478104
Sangiovanni S, Morales EI, Fernández-Trujillo L (2021) Inhaled tobramycin for chronic infection with Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respir Med 176:106283. https://doi.org/10.1016/j.rmed.2020.106283
doi: 10.1016/j.rmed.2020.106283
pubmed: 33307314
Kortright KE, Chan BK, Koff JL, Turner PE (2019) Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25:219–232. https://doi.org/10.1016/j.chom.2019.01.014
doi: 10.1016/j.chom.2019.01.014
pubmed: 30763536
Summers WC (2012) The strange history of phage therapy. Bacteriophage 2:130–133. https://doi.org/10.4161/bact.20757
doi: 10.4161/bact.20757
pubmed: 23050223
pmcid: 3442826
Eaton MD, Bayne-Jones S (1934) Bacteriophage therapy: review of the principles and results of the use of bacteriophage in the treatment of infections. J Am Med Assoc 103:1769–1776. https://doi.org/10.1001/jama.1934.72750490003007
doi: 10.1001/jama.1934.72750490003007
Marcuk LM, Nikiforov VN, Scerbak JF et al (1971) Clinical studies of the use of bacteriophage in the treatment of cholera. Bull World Health Org 45:77–83
pubmed: 4946956
pmcid: 2427894
Monsur KA, Rahman MA, Huq F et al (1970) Effect of massive doses of bacteriophage on excretion of vibrios, duration of diarrhoea and output of stools in acute cases of cholera. Bull World Health Org 42:723–732
pubmed: 4988693
pmcid: 2427496
Smith HW, Huggins MB (1982) Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128:307–318. https://doi.org/10.1099/00221287-128-2-307
doi: 10.1099/00221287-128-2-307
pubmed: 7042903
Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A (1987) Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz) 35:569–583
pubmed: 3455647
McCallin S, Sacher JC, Zheng J, Chan BK (2019) Current state of compassionate phage therapy. Viruses 11:343. https://doi.org/10.3390/v11040343
doi: 10.3390/v11040343
pubmed: 31013833
pmcid: 6521059
Schooley RT, Biswas B, Gill JJ et al (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. https://doi.org/10.1128/aac.00954-17.10.1128/aac.00954-17
doi: 10.1128/aac.00954-17.10.1128/aac.00954-17
pubmed: 28807909
pmcid: 5610518
Chan BK, Turner PE, Kim S et al (2018) Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018:60–66. https://doi.org/10.1093/emph/eoy005
doi: 10.1093/emph/eoy005
pubmed: 29588855
pmcid: 5842392
Dedrick RM, Guerrero-Bustamante CA, Garlena RA et al (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus. Nat Med 25:730–733. https://doi.org/10.1038/s41591-019-0437-z
doi: 10.1038/s41591-019-0437-z
pubmed: 31068712
pmcid: 6557439
Pirnay J-P, Djebara S, Steurs G et al (2023) Retrospective observational analysis of the first one hundred consecutive cases of personalized bacteriophage therapy of difficult-to-treat infections facilitated by a belgian consortium. medRxiv. https://doi.org/10.1101/2023.08.28.23294728
doi: 10.1101/2023.08.28.23294728
Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT (2023) Phage therapy: from biological mechanisms to future directions. Cell 186:17–31. https://doi.org/10.1016/j.cell.2022.11.017
doi: 10.1016/j.cell.2022.11.017
pubmed: 36608652
pmcid: 9827498
Mitropoulou G, Koutsokera A, Csajka C et al (2022) Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations. Eur Respir Rev. https://doi.org/10.1183/16000617.0121-2022
doi: 10.1183/16000617.0121-2022
pubmed: 36198417
pmcid: 9724797
Dedrick RM, Smith BE, Cristinziano M et al (2023) Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin Infect Dis 76:103–112. https://doi.org/10.1093/cid/ciac453
doi: 10.1093/cid/ciac453
pubmed: 35676823
Chan BK, Stanley GL, Kortright KE et al (2023) Personalized inhaled bacteriophage therapy decreases multidrug-resistant pseudomonas aeruginosa. MedRxiv. https://doi.org/10.1101/2023.01.23.22283996
doi: 10.1101/2023.01.23.22283996
pubmed: 38234828
pmcid: 10775325
Wu N, Dai J, Guo M et al (2021) Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients. Emerg Microbes Infect 10:612–618. https://doi.org/10.1080/22221751.2021.1902754
doi: 10.1080/22221751.2021.1902754
pubmed: 33703996
pmcid: 8032346
Uyttebroek S, Chen B, Onsea J et al (2022) Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis 22:e208–e220. https://doi.org/10.1016/S1473-3099(21)00612-5
doi: 10.1016/S1473-3099(21)00612-5
pubmed: 35248167
Gu Liu C, Green SI, Min L et al (2020) Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio. https://doi.org/10.1128/mbio.01462-20
doi: 10.1128/mbio.01462-20
pubmed: 32753497
pmcid: 7407087
Comeau AM, Tétart F, Trojet SN et al (2007) Phage-antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE 2:e799. https://doi.org/10.1371/journal.pone.0000799
doi: 10.1371/journal.pone.0000799
pubmed: 17726529
pmcid: 1949050
Chen Q, Dharmaraj T, Cai PC et al (2022) Bacteriophage and bacterial susceptibility, resistance, and tolerance to antibiotics. Pharmaceutics 14:1425. https://doi.org/10.3390/pharmaceutics14071425
doi: 10.3390/pharmaceutics14071425
pubmed: 35890320
pmcid: 9318951
Bulssico J, PapukashvilI I, Espinosa L et al (2023) Phage-antibiotic synergy: cell filamentation is a key driver of successful phage predation. PLoS Pathog 19:e1011602. https://doi.org/10.1371/journal.ppat.1011602
doi: 10.1371/journal.ppat.1011602
pubmed: 37703280
pmcid: 10519598
Jones D (1945) The effect of antibiotic substances upon bacteriophage12. J Bacteriol 50:341–348
doi: 10.1128/jb.50.3.341-348.1945
pubmed: 16561008
pmcid: 374147
Huff WE, Huff GR, Rath NC et al (2004) Therapeutic efficacy of bacteriophage and baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers1. Poult Sci 83:1944–1947. https://doi.org/10.1093/ps/83.12.1944
doi: 10.1093/ps/83.12.1944
pubmed: 15615004
Oechslin F, Piccardi P, Mancini S et al (2017) Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa Infection in endocarditis and reduces virulence. J Infect Dis 215:703–712. https://doi.org/10.1093/infdis/jiw632
doi: 10.1093/infdis/jiw632
pubmed: 28007922
Altamirano FLG, Kostoulias X, Subedi D et al (2022) Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. EBioMedicine. https://doi.org/10.1016/j.ebiom.2022.104045
doi: 10.1016/j.ebiom.2022.104045
Nick JA, Dedrick RM, Gray AL et al (2022) Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell 185:1860-1874.e12. https://doi.org/10.1016/j.cell.2022.04.024
doi: 10.1016/j.cell.2022.04.024
pubmed: 35568033
pmcid: 9840467
Hahn A, Sami I, Chaney H et al (2023) Bacteriophage therapy for Pan-drug-resistant Pseudomonas aeruginosa in two persons with cystic fibrosis. J Investig Med High Impact Case Rep 11:23247096231188244. https://doi.org/10.1177/23247096231188243
doi: 10.1177/23247096231188243
pubmed: 37515541
pmcid: 10387758
Kirby AE (2012) Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS ONE 7:e51017. https://doi.org/10.1371/journal.pone.0051017
doi: 10.1371/journal.pone.0051017
pubmed: 23226451
pmcid: 3511404
Coulter LB, McLean RJC, Rohde RE, Aron GM (2014) Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses 6:3778–3786. https://doi.org/10.3390/v6103778
doi: 10.3390/v6103778
pubmed: 25285538
pmcid: 4213561
Valério N, Oliveira C, Jesus V et al (2017) Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli. Virus Res 240:8–17. https://doi.org/10.1016/j.virusres.2017.07.015
doi: 10.1016/j.virusres.2017.07.015
pubmed: 28746884
Chan BK, Sistrom M, Wertz JE et al (2016) Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 6:26717. https://doi.org/10.1038/srep26717
doi: 10.1038/srep26717
pubmed: 27225966
pmcid: 4880932
Gordillo Altamirano F, Forsyth JH, Patwa R et al (2021) Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials. Nat Microbiol 6:157–161. https://doi.org/10.1038/s41564-020-00830-7
doi: 10.1038/s41564-020-00830-7
pubmed: 33432151
Kim M, Jo Y, Hwang YJ et al (2018) Phage-antibiotic synergy via delayed lysis. Appl Environ Microbiol 84:e02085-e2118. https://doi.org/10.1128/AEM.02085-18
doi: 10.1128/AEM.02085-18
pubmed: 30217844
pmcid: 6210123
Abedon ST (2019) Phage-antibiotic combination treatments: antagonistic impacts of antibiotics on the pharmacodynamics of phage th erapy? Antibiotics 8:182. https://doi.org/10.3390/antibiotics8040182
doi: 10.3390/antibiotics8040182
pubmed: 31614449
pmcid: 6963693
Martin I, Morales S, Alton EWFW, Davies JC (2023) Lytic bacteriophage is a promising adjunct to common antibiotics across cystic fibrosis clinical strains and culture models of Pseudomonas aeruginosa infection. Antibiot (Basel) 12:593. https://doi.org/10.3390/antibiotics12030593
doi: 10.3390/antibiotics12030593
Payne RJH, Jansen VAA (2002) Evidence for a phage proliferation threshold? J Virol 76:13123–13124. https://doi.org/10.1128/jvi.76.24.13123-13124.2002
doi: 10.1128/jvi.76.24.13123-13124.2002
pubmed: 12438644
pmcid: 136731
Brock TD, Wooley SO (1963) Streptomycin as an antiviral agent: mode of action. Science 141:1065–1067. https://doi.org/10.1126/science.141.3585.1065
doi: 10.1126/science.141.3585.1065
pubmed: 14043354
Kever L, Hardy A, Luthe T et al (2022) Aminoglycoside antibiotics inhibit phage infection by blocking an early step of the infection cycle. MBio. https://doi.org/10.1128/mbio.00783-22
doi: 10.1128/mbio.00783-22
pubmed: 35506667
pmcid: 9239200
Alonso JC, Sarachu AN, Grau O (1981) DNA gyrase inhibitors block development of Bacillus subtilis bacteriophage SP01. J Virol 39:855–860. https://doi.org/10.1128/JVI.39.3.855-860.1981
doi: 10.1128/JVI.39.3.855-860.1981
pubmed: 6270354
pmcid: 171318
Cairns J, Becks L, Jalasvuori M, Hiltunen T (2017) Sublethal streptomycin concentrations and lytic bacteriophage together promote resistance evolution. Philoso Trans Royal Soc B Biol Sci 372:20160040. https://doi.org/10.1098/rstb.2016.0040
doi: 10.1098/rstb.2016.0040
Sorek R, Kunin V, Hugenholtz P (2008) CRISPR — a widespread system that provides acquired resistance against phages in bacteria and archaea. Nat Rev Microbiol 6:181–186. https://doi.org/10.1038/nrmicro1793
doi: 10.1038/nrmicro1793
pubmed: 18157154
Dimitriu T, Kurilovich E, Łapińska U et al (2022) Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased spacer acquisition. Cell Host Microbe 30:31-40.e5. https://doi.org/10.1016/j.chom.2021.11.014
doi: 10.1016/j.chom.2021.11.014
pubmed: 34932986
Pons BJ, Dimitriu T, Westra ER, van Houte S (2023) Antibiotics that affect translation can antagonize phage infectivity by interfering with the deployment of counter-defenses. Proc Natl Acad Sci 120:e2216084120. https://doi.org/10.1073/pnas.2216084120
doi: 10.1073/pnas.2216084120
pubmed: 36669116
pmcid: 9942909
Burmeister AR, Fortier A, Roush C et al (2020) Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance. Proc Natl Acad Sci 117:11207–11216. https://doi.org/10.1073/pnas.1919888117
doi: 10.1073/pnas.1919888117
pubmed: 32424102
pmcid: 7260982
Kumaran D, Taha M, Yi Q et al (2018) Does treatment order matter? investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front Microbiol. https://doi.org/10.3389/fmicb.2018.00127
doi: 10.3389/fmicb.2018.00127
pubmed: 29459853
pmcid: 5807357
Torres-Barceló C, Arias-Sánchez FI, Vasse M et al (2014) A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS ONE 9:e106628. https://doi.org/10.1371/journal.pone.0106628
doi: 10.1371/journal.pone.0106628
pubmed: 25259735
pmcid: 4178015
Mukhopadhyay S, Zhang P, To KKW et al (2023) Sequential treatment effects on phage–antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 62:106951. https://doi.org/10.1016/j.ijantimicag.2023.106951
doi: 10.1016/j.ijantimicag.2023.106951
pubmed: 37574030
Uchiyama J, Shigehisa R, Nasukawa T et al (2018) Piperacillin and ceftazidime produce the strongest synergistic phage-antibiotic effect in Pseudomonas aeruginosa. Arch Virol 163:1941–1948. https://doi.org/10.1007/s00705-018-3811-0
doi: 10.1007/s00705-018-3811-0
pubmed: 29550930
Davies D (2003) Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2:114–122. https://doi.org/10.1038/nrd1008
doi: 10.1038/nrd1008
pubmed: 12563302
Hall-Stoodley L, McCoy KS (2022) Biofilm aggregates and the host airway-microbial interface. Front Cell Infect Microbiol 12:969326. https://doi.org/10.3389/fcimb.2022.969326
doi: 10.3389/fcimb.2022.969326
pubmed: 36081767
pmcid: 9445362
Gloag ES, German GK, Stoodley P, Wozniak DJ (2018) Viscoelastic properties of Pseudomonas aeruginosa variant biofilms. Sci Rep 8:9691. https://doi.org/10.1038/s41598-018-28009-5
doi: 10.1038/s41598-018-28009-5
pubmed: 29946126
pmcid: 6018706
Ceri H, Olson ME, Stremick C et al (1999) The calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771–1776. https://doi.org/10.1128/JCM.37.6.1771-1776.1999
doi: 10.1128/JCM.37.6.1771-1776.1999
pubmed: 10325322
pmcid: 84946
Yan J, Bassler BL (2019) Surviving as a community: antibiotic tolerance and persistence in bacterial biofilms. Cell Host Microbe 26:15–21. https://doi.org/10.1016/j.chom.2019.06.002
doi: 10.1016/j.chom.2019.06.002
pubmed: 31295420
pmcid: 6629468
Stewart PS (2002) Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292:107–113. https://doi.org/10.1078/1438-4221-00196
doi: 10.1078/1438-4221-00196
pubmed: 12195733
Sharma D, Misba L, Khan AU (2019) Antibiotics versus biofilm: an emerging battleground in microbial communities. Antimicrob Resist Infect Control 8:76. https://doi.org/10.1186/s13756-019-0533-3
doi: 10.1186/s13756-019-0533-3
pubmed: 31131107
pmcid: 6524306
Gordon CA, Hodges NA, Marriott C (1988) Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. J Antimicrob Chemother 22:667–674. https://doi.org/10.1093/jac/22.5.667
doi: 10.1093/jac/22.5.667
pubmed: 3145268
Wood TK, Knabel SJ, Kwan BW (2013) Bacterial persister cell formation and dormancy. Appl Environ Microbiol 79:7116–7121. https://doi.org/10.1128/AEM.02636-13
doi: 10.1128/AEM.02636-13
pubmed: 24038684
pmcid: 3837759
Azeredo J, Sutherland IW (2008) The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9:261–266. https://doi.org/10.2174/138920108785161604
doi: 10.2174/138920108785161604
pubmed: 18691087
Kovacs CJ, Rapp EM, McKenzie SM et al (2023) Disruption of biofilm by bacteriophages in clinically relevant settings. Mil Med. https://doi.org/10.1093/milmed/usad385
doi: 10.1093/milmed/usad385
pubmed: 37847552
Aslam S, Lampley E, Wooten D et al (2020) Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant Bacterial infections at a single center in the United States. Open Forum Infect Dis. https://doi.org/10.1093/ofid/ofaa389
doi: 10.1093/ofid/ofaa389
pubmed: 33005701
pmcid: 7778063
Law N, Logan C, Yung G et al (2019) Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection 47:665–668. https://doi.org/10.1007/s15010-019-01319-0
doi: 10.1007/s15010-019-01319-0
pubmed: 31102236
Guo Z, Liu M, Zhang D (2023) Potential of phage depolymerase for the treatment of bacterial biofilms. Virulence 14:2273567. https://doi.org/10.1080/21505594.2023.2273567
doi: 10.1080/21505594.2023.2273567
pubmed: 37872768
pmcid: 10621286
Karthika C, Malligarjunan N, Jothi R et al (2023) Two novel phages PSPa and APPa inhibit planktonic, sessile and persister populations of Pseudomonas aeruginosa, and mitigate its virulence in Zebrafish model. Sci Rep 13:19033. https://doi.org/10.1038/s41598-023-45313-x
doi: 10.1038/s41598-023-45313-x
pubmed: 37923820
pmcid: 10624879
Tkhilaishvili T, Lombardi L, Klatt A-B et al (2018) Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus. Int J Antimicrob Agents 52:842–853. https://doi.org/10.1016/j.ijantimicag.2018.09.006
doi: 10.1016/j.ijantimicag.2018.09.006
pubmed: 30236955
Chang RYK, Das T, Manos J et al (2019) Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients. AAPS J 21:49. https://doi.org/10.1208/s12248-019-0315-0
doi: 10.1208/s12248-019-0315-0
pubmed: 30949776
Chaudhry WN, Concepción-Acevedo J, Park T et al (2017) Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS ONE 12:e0168615. https://doi.org/10.1371/journal.pone.0168615
doi: 10.1371/journal.pone.0168615
pubmed: 28076361
pmcid: 5226664
Dickey J, Perrot V (2019) Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro. PLoS ONE 14:e0209390. https://doi.org/10.1371/journal.pone.0209390
doi: 10.1371/journal.pone.0209390
pubmed: 30650088
pmcid: 6334939
Kebriaei R, Lehman SM, Shah RM et al (2023) Optimization of phage-antibiotic combinations against Staphylococcus aureus biofilms. Microbiol Spectr 11:e04918-e4922. https://doi.org/10.1128/spectrum.04918-22
doi: 10.1128/spectrum.04918-22
pubmed: 37199616
pmcid: 10269792
Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ (2001) Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 67:2746–2753. https://doi.org/10.1128/AEM.67.6.2746-2753.2001
doi: 10.1128/AEM.67.6.2746-2753.2001
pubmed: 11375190
pmcid: 92934
Sutherland IW (1995) Polysaccharide lyases. FEMS Microbiol Rev 16:323–347. https://doi.org/10.1111/j.1574-6976.1995.tb00179.x
doi: 10.1111/j.1574-6976.1995.tb00179.x
pubmed: 7654407
Vidakovic L, Singh PK, Hartmann R et al (2018) Dynamic biofilm architecture confers individual and collective mechanisms of viral protection. Nat Microbiol 3:26–31. https://doi.org/10.1038/s41564-017-0050-1
doi: 10.1038/s41564-017-0050-1
pubmed: 29085075
Bond MC, Vidakovic L, Singh PK et al (2021) Matrix-trapped viruses can prevent invasion of bacterial biofilms by colonizing cells. Elife 10:e65355. https://doi.org/10.7554/eLife.65355
doi: 10.7554/eLife.65355
pubmed: 34240700
pmcid: 8346279
Bryan D, El-Shibiny A, Hobbs Z et al (2016) Bacteriophage T4 infection of stationary Phase E. coli: life after log from a phage perspective. Front Microbiol. https://doi.org/10.3389/fmicb.2016.01391
doi: 10.3389/fmicb.2016.01391
pubmed: 28111571
pmcid: 5014867
Łoś M, Węgrzyn G (2012) Pseudolysogeny. Adv Virus Res 82:339–349. https://doi.org/10.1016/B978-0-12-394621-8.00019-4
doi: 10.1016/B978-0-12-394621-8.00019-4
pubmed: 22420857
Ripp S, Miller RV (1998) Dynamics of the pseudolysogenic response in slowly growing cells of Pseudomonas aeruginosa. Microbiol (Read) 144:2225–2232. https://doi.org/10.1099/00221287-144-8-2225
doi: 10.1099/00221287-144-8-2225
Maffei E, Woischnig A-K, Burkolter MR et al (2024) Phage paride can kill dormant, antibiotic-tolerant cells of Pseudomonas aeruginosa by direct lytic replication. Nat Commun 15:175. https://doi.org/10.1038/s41467-023-44157-3
doi: 10.1038/s41467-023-44157-3
pubmed: 38168031
pmcid: 10761892
Mulcahy LR, Burns JL, Lory S, Lewis K (2010) Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192:6191–6199. https://doi.org/10.1128/JB.01651-09
doi: 10.1128/JB.01651-09
pubmed: 20935098
pmcid: 2981199
Jorth P, Staudinger BJ, Wu X et al (2015) Regional isolation drives bacterial diversification within cystic fibrosis lungs. Cell Host Microbe 18:307–319. https://doi.org/10.1016/j.chom.2015.07.006
doi: 10.1016/j.chom.2015.07.006
pubmed: 26299432
pmcid: 4589543
Mapes AC, Trautner BW, Liao KS, Ramig RF (2016) Development of expanded host range phage active on biofilms of multi-drug resistant Pseudomonas aeruginosa. Bacteriophage 6:e1096995. https://doi.org/10.1080/21597081.2015.1096995
doi: 10.1080/21597081.2015.1096995
pubmed: 27144083
pmcid: 4836484
Du J, Meile S, Baggenstos J et al (2023) Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors. Nat Commun 14:4337. https://doi.org/10.1038/s41467-023-39612-0
doi: 10.1038/s41467-023-39612-0
pubmed: 37474516
pmcid: 10359290
Schmerer M, Molineux IJ, Bull JJ (2014) Synergy as a rationale for phage therapy using phage cocktails. PeerJ 2:e590. https://doi.org/10.7717/peerj.590
doi: 10.7717/peerj.590
pubmed: 25279269
pmcid: 4179555
Haines MEK, Hodges FE, Nale JY et al (2021) Analysis of selection methods to develop novel phage therapy cocktails against antimicrobial resistant clinical isolates of bacteria. Front Microbiol. https://doi.org/10.3389/fmicb.2021.613529
doi: 10.3389/fmicb.2021.613529
pubmed: 33868187
pmcid: 8044893
Zurabov F, Petrova M, Zurabov A et al (2023) Adaptive phage therapy for the prevention of recurrent nosocomial pneumonia: novel protocol description and case series. Antibiotics 12:1734. https://doi.org/10.3390/antibiotics12121734
doi: 10.3390/antibiotics12121734
pubmed: 38136768
pmcid: 10741035
Chan BK, Stanley G, Modak M et al (2021) Bacteriophage therapy for infections in CF. Pediatr Pulmonol 56:S4–S9. https://doi.org/10.1002/ppul.25190
doi: 10.1002/ppul.25190
pubmed: 33434411
Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317–327. https://doi.org/10.1038/nrmicro2315
doi: 10.1038/nrmicro2315
pubmed: 20348932
Torres-Barceló C, Turner PE, Buckling A (2022) Mitigation of evolved bacterial resistance to phage therapy. Curr Opin Virol 53:101201. https://doi.org/10.1016/j.coviro.2022.101201
doi: 10.1016/j.coviro.2022.101201
pubmed: 35180532
Dedrick RM, Smith BE, Garlena RA et al (2021) Mycobacterium abscessus strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance. Micro biol. https://doi.org/10.1128/mbio.03431-20
doi: 10.1128/mbio.03431-20
Aslam S, Courtwright AM, Koval C et al (2019) Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant 19:2631–2639. https://doi.org/10.1111/ajt.15503
doi: 10.1111/ajt.15503
pubmed: 31207123
pmcid: 6711787
Wang X, Xie Z, Zhao J et al (2021) Prospects of inhaled phage therapy for combatting pulmonary infections. Front Cell Infect Microbiol 11:758392. https://doi.org/10.3389/fcimb.2021.758392
doi: 10.3389/fcimb.2021.758392
pubmed: 34938668
pmcid: 8685529
Astudillo A, Leung SSY, Kutter E et al (2018) Nebulization effects on structural stability of bacteriophage PEV 44. Eur J Pharm Biopharm 125:124–130. https://doi.org/10.1016/j.ejpb.2018.01.010
doi: 10.1016/j.ejpb.2018.01.010
pubmed: 29353018
Dedrick RM, Freeman KG, Nguyen JA et al (2021) Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat Med 27:1357–1361. https://doi.org/10.1038/s41591-021-01403-9
doi: 10.1038/s41591-021-01403-9
pubmed: 34239133
pmcid: 8571776
Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG (2023) CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet 402:1171–1184. https://doi.org/10.1016/S0140-6736(23)01609-4
doi: 10.1016/S0140-6736(23)01609-4
pubmed: 37699418
Ledger EL, Smith DJ, Teh JJ et al (2024) Impact of CFTR modulation on Pseudomonas aeruginosa infection in people with cystic fibrosis. J Infect Dis. https://doi.org/10.1093/infdis/jiae051
doi: 10.1093/infdis/jiae051
pubmed: 38442240
Nichols DP, Morgan SJ, Skalland M et al (2023) Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density but lung infections generally persist. J Clin Invest. https://doi.org/10.1172/JCI167957
doi: 10.1172/JCI167957
pubmed: 37733448
pmcid: 10645395